Cancer cell plasticity is viewed as a driver of therapy resistance. Here, we propose the concept of “Field-Oriented” Therapy—leveraging plasticity rather than merely enduring it. To learn more, read: aacrjournals.org/cancerdiscov...
Intra-tumour heterogeneity (ITH) and cellular plasticity contribute to therapy resistance. Single-cell transcriptomics is the gold standard for assessing ITH, but this approach remains costly and slow...
